Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ: PRTA )

13.77 +0.59 (+4.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 Next >
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
From Walgreens
Via Business Wire
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in Stifel 2023 Virtual CNS Days
From Prothena Corporation plc
Via Business Wire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
Exposures COVID-19
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
From Prothena Corporation plc
Via Business Wire
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Prothena Announces Proposed Public Offering of Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
From Prothena Corporation plc
Via Business Wire
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
From Prothena Corporation plc
Via Business Wire
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
From Prothena Corporation plc
Via GlobeNewswire
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
Cognitive Assessment And Training Market Size Expected To Reach $15.65 Billion In 2028
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.